4 stories mentioning KYMRUpdated just now
Every FINWIRES story that references KYMR, newest first.
Bruce Booth, Director, on June 17, 2026, sold 478,198 shares in Kymera Therapeutics (KYMR) for $45,293,294. Following the Form 4 filing with the SEC, Booth has control over a total of 4,108,316 common shares of the company, with 4,108,316 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1815442/000145161226000010/xslF345X05/form4-06232026_010608.xml
Bruce Booth, Director, on June 17, 2026, sold 31,798 shares in Kymera Therapeutics (KYMR) for $3,299,037. Following the Form 4 filing with the SEC, Booth has control over a total of 4,076,518 common shares of the company, with 4,076,518 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1815442/000145161226000012/xslF345X05/form4-06232026_010614.xml
Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $118.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Kymera Therapeutics (KYMR) shares were down 3% in Thursday trading after it reported a Q1 loss of $0.71 per share, narrowing from a loss of $0.82 a year earlier.Analysts surveyed by FactSet expected a loss of $0.88.Collaboration revenue for the quarter ended March 31 was $34.4 million, up from $22.1 million a year earlier.Analysts polled by FactSet expected $8.3 million.As of March 31, Kymera Therapeutics said it had $1.55 billion in cash, cash equivalents, and investments, which it expects to provide the company with a cash runway into 2029.Price: $79.23, Change: $-2.28, Percent Change: -2.80%
